Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.


The Atlantic
Accessed 24 Oct 2020
[No new, unique, relevant content]


Accessed 24 Oct 2020
[No new, unique, relevant content]


The Economist
Accessed 24 Oct 2020
Controlling the pandemic
Should covid be left to spread among the young and healthy
Two petitions by scientists clash on the matter
Oct 21st 2020 edition


Financial Times
Accessed 24 Oct 2020

Coronavirus treatment
Vaccine deal allows AstraZeneca to take up to 20% on top of costs
Drugmaker says non-manufacturing expenses will exceed $1bn in Oxford virus project
23 Oct 2020
AstraZeneca’s confidential coronavirus vaccine deal with Oxford university allows it to make as much as 20 per cent on top of the cost of goods for manufacturing the jab, according to people with knowledge of the contract.
UK-headquartered AstraZeneca has pledged to sell the vaccine “at cost” during the pandemic, eschewing profits. It has declined to say how much the vaccine costs to make.
Observers have expr essed fears over a lack of transparency around the global deals involving the supply of potential vaccines.
AstraZeneca insisted it treated the development of a vaccine as a public health emergency and not a profitmaking opportunity, saying more than $1bn of its costs incurred in the project, for example regulatory submissions and distribution, were not related to manufacturing…


Accessed 24 Oct 2020
Breaking  |  Oct 23, 2020
Trump Hasn’t Shown Up To Covid Task Force In Months, Fauci Says
Controversial advisor Dr. Scott Atlas apparently has the president’s ear more than Dr. Anthony Fauci.
By Joe Walsh Forbes Staff

Coronavirus  |  Oct 23, 2020
Three Takeaways From Major FDA Advisory Meeting On Covid-19 Vaccines
One thing became clear over the course of the seven-hour meeting — that a hastily expedited vaccine might benefit some people, but fail those who need protection most.
By William A. Haseltine Contributor

Coronavirus  |  Oct 22, 2020
Vaccine Transporters Feel Unprepared For The Distributive Effort Ahead
As pharmaceutical companies conduct phase 3 vaccine trials, air cargo transporters are cautious about the logistics involved in the mass distribution of a Covid-19 vaccine.
By William A. Haseltine Contributor

Breaking  |  Oct 21, 2020
Bolsonaro Clashes With His Own Government Over Chinese Coronavirus Vaccine
“For sure, we will not buy the Chinese vaccine,” Bolsonaro said.
By Carlie Porterfield Forbes Staff


Foreign Affairs
Accessed 24 Oct 2020
Fighting a Pandemic Requires Trust
Governments Have to Earn It
Thomas J. Bollyky, Sawyer Crosby, and Samantha Kiernan
October 23, 2020


Foreign Policy
Accessed 24 Oct 2020
[No new, unique, relevant content]


The Guardian
Accessed 24 Oct 2020
[No new, unique, relevant content]


New Yorker
Accessed 24 Oct 2020
Medical Dispatch
How Trump Became the Pro-Infection Candidate
By embracing the Great Barrington Declaration—a fringe document advocating mass transmission of the coronavirus—the White House has achieved a new, lunatic level of denial.
By Dhruv Khullar
October 23, 2020


New York Times
Accessed 24 Oct 2020
After pausing for safety concerns, AstraZeneca and Johnson & Johnson have resumed their U.S. vaccine trials.
Oct. 23 By Katherine J. Wu and Carl Zimmer

The Trump Administration Shut a Vaccine Safety Office Last Year. What’s the Plan Now?
The office was dedicated to the long-term safety of vaccines. Experts say plans to track coronavirus vaccines are fragmented and “behind the eight ball.”
Oct. 23 By Carl Zimmer


Washington Post
Accessed 24 Oct 2020
Stressing freedom, vaccine opponents rebranding in virus era
Oct 22, 2020